Methylene blue aids observation of the procedure and assessment of drug distribution.
Adding methylene blue to onabotulinum toxin A (BTX-A) solution for thetreatment of overactive bladder (OAB) facilitates observation of the procedureand assessment of drug distribution, researchers reported online ahead ofprint in the Scandinavian Journal of Urology.
Michal Szczypior, MD, and colleagues at the Medical University of Gdansk inPoland tested this approach in 30 patients (24 women and 6 men) with OAB whoqualified for BTX-A injections. Each patients received 100 IU of BTX-A dissolvedin 9.5 mL of 0.9% sodium chloride solution, with 0.5 mL of methylene blue added.Over the course of 600 injections, the investigators reported that they were unableto observe the exact distribution of the solution in only 43 injections in 7 patients.They found no pharmacologic interactions between methylene blue and BTX-A.
Enjoying our content?
Thanks for visiting Renal & Urology News. We hope you’re enjoying the latest clinical news, full-length features, case studies, and more.
You’ve viewed {{metering-count}} of {{metering-total}} articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.
{{login-button}} {{register-button}}
Log in to continue reading this article.
Don’t miss out on today’s top content on Renal & Urology News. Register for free and gain unlimited access to:
- Clinical News, with personalized daily picks for you
- Case Studies
- Conference Coverage
- Full-Length Features
- Drug Monographs
- And More
{{login-button}} {{register-button}}
Want to read more?
Please login or register first to view this content.